Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 27;3(1):vdaa162. doi: 10.1093/noajnl/vdaa162

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — Validation set analysis showing glycolytic expression (same gene set from Figure 2) predicts patient isocitrate hydrogenase (IDH) status and alternative co-methylation landscapes. (A) Heatmap of patient clusters produced using 23 metabolic genes (blue row labels = IDH wild-type samples; red labels = IDH mutant samples). Cluster2 is significantly enriched for IDH-wild type patients (P < .0001, x² = 76.76). (B) OS analysis between clusters shows cluster2 patients are associated with significantly worse OS (P < .0001, HR = 2.76 [1.66–4.60]). (C,D) Co-methylation heatmap clustering (Pearson correlation values) of CpG cites for cluster1 (C) and cluster2 (D). Cluster1 (IDH mutant enriched) displays more heterogeneity across methylation sites while cluster2 (IDH mutant enriched) appeared more uniformly correlated.